Glenmede Trust CO Na Fibrogen Inc Transaction History

Glenmede Trust CO Na

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $140,110 - $269,205	-7,545 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$31.0 - $55.72 $2,635 - $4,736	85 Added 1.14%	7,545 $261,000
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $27,817 - $36,727	750 Added 11.18%	7,460 $276,000
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $68,191 - $76,667	1,685 Added 33.53%	6,710 $275,000
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $163,664 - $215,220	5,025 New	5,025 $203,000
Q1 2019 May 14, 2019	SELL	$42.83 - $59.91 $10,065 - $14,078	-235 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $8,922 - $14,137	235 New	235 $10,000
Q3 2018 Nov 15, 2018	SELL	$56.3 - $67.25 $66,997 - $80,027	-1,190 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$44.9 - $64.95 $53,431 - $77,290	1,190 New	1,190 $74,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.